Hormone replacement therapy post Women's Health Initiative study: where do we stand?

被引：8

作者：

Calleja-Agius, Jean ^{[1
]}

Brincat, Mark P. ^{[1
]}

机构：

[1] Mater Dei Hosp, Dept Obstet & Gynaecol, Msida, Malta

来源：

CURRENT OPINION IN OBSTETRICS & GYNECOLOGY | 2008年 / 20卷 / 06期

关键词：

hormone replacement therapy; oestrogen; progesterone; Women's Health Initiative;

D O I：

10.1097/GCO.0b013e32830dfa5c

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Purpose of review The aim of this review is to look at all publications from the past 18 months, which deal with the impact of the Women's Health Initiative Trial on hormone replacement therapy. Recent findings There is a definite decline in the use of hormone replacement therapy among menopausal women. Summary More research needs to be done on the long-term effects of hormone replacement therapy, especially with regard to ultra-low dose hormone therapy.

引用

页码：513 / 518

页数：6

共 40 条

[31] Conjugated equine estrogens and breast cancer risk in the women's health initiative clinical trial and observational study
Prentice, Ross L.
Chlebowski, Rowan T.
Stefanick, Marcia L.
Manson, JoAnn E.
Langer, Robert D.
Pettinger, Mary
Hendrix, Susan L.
Hubbell, F. Allan
Kooperberg, Charles
Kuller, Lewis H.
Lane, Dorothy S.
McTiernan, Anne
O'Sullivan, Mary Jo
Rossouw, Jacques E.
Anderson, Garnet L.
[J]. AMERICAN JOURNAL OF EPIDEMIOLOGY, 2008, 167 (12) : 1407 - 1415
[32] Rees Margaret, 2008, Menopause Int, V14, P40, DOI 10.1258/mi.2007.007037
[33] Rockhill B, 2000, AM J EPIDEMIOL, V151, P404
[34] Risks and benefits of estrogen plus progestin in healthy postmenopausal women - Principal results from the Women's Health Initiative randomized controlled trial
Rossouw, JE
Anderson, GL
Prentice, RL
LaCroix, AZ
Kooperberg, C
Stefanick, ML
Jackson, RD
Beresford, SAA
Howard, BV
Johnson, KC
Kotchen, JM
Ockene, J
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (03): : 321 - 333
[35] Helping midlife women predict the onset of the final menses: SWAN, the Study of Women's Health Across the Nation
Santoro, Nanette
Brockwell, Sarah
Johnston, Janet
Crawford, Sybil L.
Gold, Ellen B.
Harlow, Sioban D.
Matthews, Karen A.
Sutton-Tyrrell, Kim
[J]. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2007, 14 (03): : 415 - 424
[36] Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women - The Women's Health Initiative Memory Study: A randomized controlled trial
Shumaker, SA
Legault, C
Rapp, SR
Thal, L
Wallace, RB
Ockene, JK
Hendrix, SL
Jones, BN
Assaf, AR
Jackson, RD
Kotchen, JM
Wassertheil-Smoller, S
Wactawski-Wende, J
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (20): : 2651 - 2662
[37] Consequenses for HRT following the HERS II and WHI reports:: The primum non nocere is important, but translation into quo vadis is even more essential
Skouby, SO
[J]. ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2002, 81 (09) : 793 - 798
[38] Endometrial safety and bleeding with HRT: what's new?
Sturdee, D. W.
[J]. CLIMACTERIC, 2007, 10 : 66 - 70
[39] The Women's International Study of Long-duration Oestrogen after Menopause (WISDOM): A randomised controlled trial
Vickers M.R.
Martin J.
Meade T.W.
Arasaratnum N.
Collins N.
Furness P.
Ghali M.
Gordon E.
Huppert F.
Islam Z.
Knott C.
Meredith S.
Prince M.
Purdon S.
Richards M.
Taylor L.
Welton A.
Zhu C.-Q.
Zuhrie R.
Dowell A.
Lawton B.
Lawton B.
MacLennon A.
[J]. BMC Women's Health, 7 (1)
[40] Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women
Vickers, Madge R.
MacLennan, Alastair H.
Lawton, Beverley
Ford, Deborah
Martin, Jeannett
Meredith, Sarah K.
DeStavola, Bianca L.
Rose, Sally
Dowell, Anthony
Wikes, Helen C.
Darbyshire, Janet H.
Meade, Tom W.
[J]. BMJ-BRITISH MEDICAL JOURNAL, 2007, 335 (7613): : 239 - +

← 1 2 3 4 →